CARBIDOPA
Clinical safety rating: safe
Animal studies have demonstrated safety
Carbidopa inhibits peripheral decarboxylation of levodopa, increasing levodopa availability to the brain.
| Metabolism | Not extensively metabolized; primarily excreted unchanged in urine. Minor metabolism via O-methylation and conjugation. |
| Excretion | Renal: 70% as metabolites, 30% unchanged; biliary/fecal: minimal (<5%). |
| Half-life | 1-2 hours (terminal); clinically, coadministration with carbidopa does not alter levodopa half-life but reduces peripheral metabolism. |
| Protein binding | ~36% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | 0.36 L/kg; distributes into total body water, does not significantly cross blood-brain barrier. |
| Bioavailability | Oral: ~100% (carbidopa is fully absorbed but not used therapeutically alone; bioavailability of levodopa is increased from ~30% to ~75% with carbidopa). |
| Onset of Action | Oral: 30-60 minutes (as monotherapy, though typically given with levodopa; carbidopa alone has no antiparkinsonian effect). |
| Duration of Action | Oral: 4-6 hours (when combined with levodopa, extends duration of levodopa effect by inhibition of peripheral decarboxylation). |
Oral, 25 mg carbidopa with 100 mg levodopa (Sinemet 25/100) three times daily, titrated based on response. Maximum 200 mg carbidopa per day.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for GFR >30 mL/min. For GFR 15-30 mL/min, reduce dose by 50% and monitor. Avoid use if GFR <15 mL/min. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% and monitor. Child-Pugh C: avoid use. |
| Pediatric use | Not FDA-approved for pediatric use. Dosing based on levodopa: start at 1-2 mg/kg/dose of carbidopa with 10-20 mg/kg/dose of levodopa three times daily, titrated to effect. Maximum carbidopa 10 mg/kg/day. |
| Geriatric use | Start at lower initial doses (e.g., carbidopa 12.5 mg with levodopa 50 mg twice daily) and titrate slowly due to increased risk of adverse effects and comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Nonselective MAOIs are contraindicated When given without levodopa it has no therapeutic effect.
| Breastfeeding | Excreted into breast milk in low amounts; M/P ratio unknown. No adverse effects reported in infants. However, consider benefit of therapy and potential for infant exposure; recommend monitoring infant for signs of dopamine receptor blockade (e.g., extrapyramidal effects). |
| Teratogenic Risk | Limited human data; animal studies show no teratogenicity at clinically relevant doses. Use only if benefit outweighs risk (FDA Pregnancy Category C). First trimester: possible association with cardiovascular defects? Second and third trimesters: no documented fetal harm. |
■ FDA Black Box Warning
None
| Common Effects | Nausea |
| Serious Effects |
["Hypersensitivity to carbidopa","Concomitant use with nonselective MAO inhibitors (e.g., phenelzine, tranylcypromine)"]
| Precautions | ["May cause dyskinesias or psychiatric disturbances when combined with levodopa","Use with caution in patients with severe cardiovascular or pulmonary disease","Risk of neuroleptic malignant syndrome-like symptoms upon abrupt withdrawal"] |
| Food/Dietary | High-protein meals can reduce levodopa absorption and effectiveness; distribute protein intake evenly throughout the day. Avoid taking with iron supplements or multivitamins containing iron as they chelate levodopa. Vitamin B6 (pyridoxine) in high doses may counteract levodopa effects when used without carbidopa; but with carbidopa, this interaction is minimized. No specific restrictions with grapefruit. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure and symptoms of parkinsonism; periodic fetal ultrasound for growth and development if used during first trimester; assess for maternal adverse effects (e.g., nausea, dyskinesia). |
| Fertility Effects | No known effects on fertility in women; in men, no studies available. Carbidopa may improve sexual function related to Parkinson's disease control. |
| Clinical Pearls | Carbidopa is a peripheral decarboxylase inhibitor that prevents the conversion of levodopa to dopamine outside the CNS, reducing peripheral side effects and increasing levodopa availability to the brain. It is always used in combination with levodopa. Onset of clinical effect is typically within 1-2 hours. Common side effects include dyskinesias and nausea; nausea can be mitigated by taking with food. Abrupt discontinuation may precipitate neuroleptic malignant syndrome. Monitor for hallucinations, confusion, and orthostatic hypotension. |
| Patient Advice | Take exactly as prescribed; do not stop suddenly without consulting your doctor. · This medication is always combined with levodopa; do not take carbidopa alone. · May cause dizziness or drowsiness; avoid driving until you know how it affects you. · If you experience nausea, take with a low-protein snack or meal. · Report any unusual movements, confusion, or dark-colored urine to your doctor. · Avoid alcohol as it can increase side effects. |